To examine the association of serum anti-Müllerian hormone (AMH) levels with biochemical derangement and sonographic appearance in PCOS women and to examine its role as a possible marker for diagnosis and prognosis of polycystic ovarian syndrome (PCOS). Materials and methods: This case-control study was conducted on patients attending the Gynecology OPD at ESIC Medical College and Hospital, Faridabad, Haryana from March 2017 to September 2017. 45 PCOS women and controls between 18 years and 45 years were recruited. Relevant clinical, biochemical, and sonographic data were collected. Linear regression was used to study the association between biochemical and sonographic variables and PCOS. Receiver-operating characteristic (ROC) curve analysis was performed for AMH, LH/FSH ratio, antral follicle count (AFC), and mean ovarian volume. The AMH cut-off value was determined for the prediction of PCOS. Results: Mean AMH levels were significantly higher in the PCOS group (5.9 v/s 2.36 ng/mL). In PCOS women, AMH levels positively correlated with AFC, mean ovarian volume, as well as androstenedione and testosterone levels. In controls, a significant positive correlation was found with serum testosterone and mean ovarian volume. An AMH had greater diagnostic potential for detecting PCOS compared to AFC, mean ovarian volume, and LH/FSH ratio. A threshold AMH value of 3.98 ng/mL had a sensitivity of 82.2% and a specificity of 93.3% for diagnosing PCOS. Conclusion: Serum AMH levels correlate well with hyperandrogenemia and sonographic features of PCOS and could be used as a marker for hormonal dysfunction and disease severity. Clinical significance: An AMH is a promising marker that could improve the diagnosis of PCOS and also help in establishing disease severity.
Ethical Committee before commencing the study. As per the Rotterdam/ESHRE criteria 2003, 9 PCOS was defined as the presence of at least two of the following:
• Oligo/anovulation • Hyperandrogenism and/or hyperandrogenemia • Polycystic ovaries (>12 follicles measuring 2-9 mm in one/both ovaries and/or increased ovarian volume >10 mL in one or both ovaries)
Women with hepatic, renal and autoimmune diseases, abnormal serum albumin, overt hyper/hypothyroidism, and adrenal disorders were excluded. Those with the history of use of hormones, ovulation-induction drugs, and insulin-sensitizing drugs in the past 3 months were excluded from the study. Past history of ovarian drilling was also an exclusion criterion.
Relevant clinical data such as age, number of menstrual cycles per year, and history of acne and hirsutism were obtained. Anovulation was defined as the absence of spontaneous menses for 3 months. Oligo-ovulation was defined as fewer than 9 menstrual cycles per year. Hyperandrogenism was determined by hirsuitism (Ferriman Gallaway score >8) and/or the presence of acne. Hyperandrogenemia was defined as serum total testosterone >2.5 nmol/L or free testosterone >0.6 nmol/L. Body mass index (BMI) was calculated as weight (kg)/height (m 2 ).
Serum Sampling
An estimated 8 mL blood was drawn between days 2 and 5 of natural or progesterone-induced menses in overnight-fasting women. Of this blood, 6 mL was immediately used for determination of serum FSH, LH, TSH, prolactin, androstenedione, DHEAS, total testosterone, SHBG, fasting insulin, hs-CRP, SGOT, SGPT, serum albumin, LDL, HDL, and total cholesterol levels. A total of 2 mL was stored in lithium heparin test tubes at 4°C and analyzed for serum AMH levels within 24 hours.
AMH Assay
Samples were brought to room temperature (23 ± 2°C). AMH levels were assessed using the Ultrasensitive AMH/MIS ELISA (AL-105i) (Ansh Labs, Webster, Texas, USA), which is a quantitative threestep sandwich-type immunoassay. The limit of detection was 0.023 ng/mL with 95% probability. The inter-assay and intra-assay coefficients of variation were 3.2% and 3.8%, respectively.
Ultrasound Examination
A transvaginal scan was performed with a Philips C9-4v Endocavitary Probe between days 2 and 5 of the menstrual cycle. Where transvaginal scanning was not acceptable, a transabdominal scan was performed using a Philips C5-2 Convex Probe. Ovarian volume was calculated as 0.532 × length × width × height. Antral follicle count included all follicles between 2 and 9 mm size. All measurements were taken on Philips ClearVue 350 (Philips Ultrasound, Inc., Bothell, WA, USA). Those with ovarian cysts or lead follicle >10 mm in diameter were excluded from the study.
Statistical Analysis
Statistical analysis was performed by SPSS Version 16 (SPSS Inc, Chicago, IL, USA). Equality of means was compared using student's t test. Categorical variables were analyzed by Chi-square test. A p value < 0.05 was considered significant. Linear regression was used to study the association between biochemical and sonographic variables and PCOS. Receiver-operating characteristic (ROC) curve analysis was performed for AMH, LH/FSH ratio, antral follicle count (AFC), and mean ovarian volume. AUC estimates were calculated for each parameter to determine the probability of accurately discriminating between PCOS cases and controls. An optimal AMH cut-off value was determined for prediction of PCOS with acceptable sensitivity and specificity.
results
The baseline clinical, hormonal, and sonographic characteristics of cases and controls are listed in Table 1 . Cases and controls were similar with respect to age and BMI. Mean serum AMH levels were significantly higher in the PCOS group compared to controls (5.9 ± 2.0 ng/mL vs 2.36 ± 0.88 ng/mL, p < 0.05). The mean serum LH levels; LH/FSH ratio; serum-free testosterone, androstenedione, and DHEAS levels; ovarian volume; and antral follicle count were significantly higher in the PCOS group compared to controls. There was no statistically significant difference in the two groups with respect to clinical hyperandrogenism, serum FSH, TSH, Prolactin, SHBG, fasting insulin levels, and lipid profile.
In PCOS women, AMH levels correlated negatively with age (r = −0.420) and BMI (r = −0.699). A significant positive correlation was observed between AMH and androstenedione levels (r = 0.508) and serum testosterone levels (r = 0.376). No such correlation was observed with DHEAS. Similarly no correlation was observed between AMH levels and lipid profile or fasting insulin levels. AMH levels correlated strongly with both sonographic markers studied-AFC (r = 0.583) and mean ovarian volume (r = 0.591) ( Table 2 and Fig. 1 ).
In controls, unlike in cases, no correlation was observed with age or BMI. AMH levels correlated positively with serum FSH levels (r = 0.351), testosterone levels (r = 0.592), and mean ovarian volume (r = 0.511) ( Table 2 and Fig. 2 ). The diagnostic potential of serum AMH was analyzed by an ROC curve analysis. AUC for AMH was 0.987. AMH had greater diagnostic potential for detecting PCOS compared to AFC, mean ovarian volume, and LH/FSH ratio (Fig. 3) .
A threshold AMH value of 3.98 ng/mL had a sensitivity of 82.2% and a specificity of 93.3% for diagnosing PCOS.
dIscussIon
Polycystic ovarian syndrome is a multiorgan endocrine disorder with considerable phenotypic heterogeneity and ever-changing diagnostic criteria which are subject to interobserver and intraobserver variability. There is, therefore, a need for identification of more precise and objective markers for the diagnosis and prognosis of PCOS.
Since AMH is produced by pre-antral and small antral follicles, its levels are expected to an increase in PCOS, where such follicles are in abundance. AMH likely exerts an inhibitory effect on the FSH-mediated folliculogenesis process and results in anovulation. A higher AMH/AFC ratio observed in PCOS indicates not only a greater number of antral follicles but also an increased production of AMH per antral follicle. 10 This observation is supported by in vitro studies, which also demonstrate greater AMH production per granulosa cell in polycystic ovaries compared to controls. 11 We observed significantly higher serum AMH levels in PCOS patients compared to controls, which is in agreement with other researchers. 12 -15 The AMH levels are reported to be higher in more severe disease phenotypes 16 and correlate well with the individual features in the Rotterdam criteria. 17 , 18 In our study, a significant negative correlation was seen between age and AMH levels in PCOS women. No such relationship was observed in controls. Laven et al. have also reported a significant negative correlation between age and AMH levels in both WHO Class 2 Infertile women and in controls. The decline with increasing age was more pronounced in PCOS women. 7 Conversely, others have reported that PCOS blunts age-related decline in AMH levels. 19 The mean age of PCOS women and controls in our study group was 24.1 ± 4.7 years and 25.2 ± 4.6 years, respectively. Since our study group and controls constituted primarily of relatively young women who are removed from the age of natural ovarian decline, we cannot conclusively comment on the impact of age on AMH levels in PCOS women.
It is observed that androgens promote the accumulation of small follicles and granulosa cells, thereby increasing AMH production. 7 Wiweko et al. have observed that AMH values correlate with rising androgen levels and are highest for the phenotype exhibiting all three Rotterdam criteria. AMH also had a higher strength of association with PCOS (OR = 6.80) compared to the serum LH and FSH level (OR = 5.90 and 4.90 respectively). 15 In the present study, AMH levels correlated well with serum testosterone and androstenedione levels in PCOS women. A significant positive correlation was seen only with testosterone but not with androstenedione in controls. Similarly, in another study on women undergoing controlled ovarian stimulation, higher AMH levels were reported than in controls and the increase was greater among women with hyperandrogenism. 20 Serum AMH levels also correlated with serum LH (r = 0.003, p = 0.0001) and mean testosterone levels (r = 0.477, p = 0.0001) in WHO class 2 infertile women compared to matched controls. 7 In 2,241 women of reproductive age with hyperandrogenic features with 17 hydroxy progesterone >2 ng/mL, serum AMH was significantly higher in those with PCOS than those with a late-onset congenital adrenal hyperplasia. They had suggested that serum AMH might be useful as a marker for PCOS in hyperandrogenic patients. 21 Other researchers have also pointed to a positive correlation between androgens and AMH levels. 12 , 22 AMH has been suggested as a substitute for sonographic findings especially where imaging is unavailable or is likely to be sub-optimal as in obesity and virginal status. Our data show a strong positive correlation of AMH levels with the mean ovarian volume and antral follicle count in PCOS women and with the mean ovarian volume alone in controls. Eilertsen et al. have reported that AMH levels are a good substitute for PCO morphology in the diagnosis of PCOS by both AES and Rotterdam criteria. 23 Other researchers have also demonstrated a positive correlation of AMH levels with ovarian volume and antral follicle count. 7 , 24 , 25 In our study, AMH was found to have good diagnostic potential for PCOS even as a stand-alone marker. It is a better predictor of PCOS than other parameters such as LH/FSH ratio, AFC and mean ovarian volume. Sahmay et al. have also suggested that AMH could serve as an important diagnostic marker in PCOS women with low or normal serum LH levels or normal LH/FSH ratio. 13 They found that at a cut off of 3.8 ng/mL AMH had 81.6% sensitivity and 85.1% specificity for diagnosis of PCOS. Multiple authors have reported moderate to good sensitivity and specificity in predicting PCOS at levels ranging from 3.44 to 5.0 ng/mL 12 -15 , 25 (Table 3) . However, a consensus on a single cut-off value remains elusive.
Researchers are examining the role of AMH as an adjunct and also as a replacement of the traditional PCOS criteria to improve the diagnosis of this disorder. 12 , 13 It is therefore poised to emerge as an objective, reliable marker for disease severity and associated hormonal dysfunction in PCOS.
conclusIon
Polycystic ovarian syndrome is associated with higher AMH levels than controls. At a cutoff value of 3.98 ng/mL, AMH has a sensitivity of 82.2% and specificity of 93.3% for diagnosis of PCOS. Its ability to predict PCOS is greater than that of AFC, mean ovarian volume, and LH/FSH levels. It correlates well with hyperandrogenemia and sonographic features of PCOS and could be used as a marker for androgen dysfunction and disease severity. 
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